Healthcare
Live Price
Offline$47.84
+0.10% today
1Y Change
-29.98%
Window
Jun 27, 2025 → Jun 24, 2026
Coverage: 249 bars · Jun 27, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Novo Nordisk A/S (NONOF) is a Healthcare stock with a market cap of $1.24T and listed on OTC. The stock last traded around $47.84 and down 30.0% across the available one-year price window (Jun 27, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of +6.2%, EPS growth of +1.4%, a dividend yield of 4.2%. What stands out right now is revenue +6.2%, EPS +1.4%, free cash flow -15.5% with operating margin 41.3% and ROIC 29.5%. The dividend matters to the case here, with a current yield around 4.2%. Valuation is more restrained than many high-expectation growth names at P/E 12.1 and price/sales 4.0. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines NONOF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NONOF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NONOF Max Drawdown
-50.04%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for NONOF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$140.8B
-20.4% YoY
FY Net Income
$47.8B
-14.0% YoY
Free Cash Flow
$47.6B
-25.8% YoY
Revenue Growth
+6.2%
EPS Growth
+1.4%
Gross Margin
81.0%
Net Margin
33.1%
Income statement
DKK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 308.4B | 290.4B | 232.3B | 177.0B | 140.8B |
| Gross Profit | 247.7B | 245.9B | 196.5B | 148.5B | 117.1B |
| Operating Income | 134.7B | 128.3B | 102.6B | 74.8B | 58.6B |
| EBITDA | 149.1B | 137.4B | 111.0B | 76.8B | 64.8B |
| Net Income | 102.2B | 101.0B | 83.7B | 55.5B | 47.8B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
DKK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 26.4B | 15.7B | 14.4B | 12.7B | 10.7B |
| Total Assets | 541.7B | 465.8B | 314.5B | 241.3B | 194.5B |
| Total Liabilities | 348.1B | 322.3B | 207.9B | 157.8B | 123.8B |
| Shareholder Equity | 193.6B | 143.5B | 106.6B | 83.5B | 70.7B |
| Total Debt | 137.9B | 102.8B | 27.0B | 25.8B | 26.6B |
| Net Debt | 111.5B | 87.1B | 12.6B | 13.1B | 15.9B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
55.0B
-30.3% YoY
Capital Expenditures
7.4B
+49.9% YoY
Free Cash Flow
47.6B
-25.8% YoY
Key ratios
Gross Margin
81.0%
Operating Margin
41.3%
Net Margin
33.1%
ROE
61.1%
Debt / Equity
0.67x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.